Free Trial
NASDAQ:VANI

Vivani Medical Q1 2026 Earnings Results & Report

Vivani Medical logo
$0.98 -0.15 (-12.97%)
Closing price 11/12/2026 04:00 PM Eastern
Extended Trading
$0.98 -0.01 (-0.85%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vivani Medical met analyst earnings expectations in its Q1 2026 results, released May 13, 2026. The company reported EPS of -$0.08 versus the -$0.08 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Vivani Medical EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.08
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Vivani Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vivani Medical Q1 2026 Earnings FAQ

Vivani Medical (NASDAQ:VANI) reported earnings of -$0.08 per share for Q1 2026, matching the consensus estimate of -$0.08. The report was announced on Wednesday, May 13, 2026.

Vivani Medical Earnings Headlines

Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Vivani Nears Key Data Readout For Obesity Implant
See More Vivani Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivani Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivani Medical and other key companies, straight to your email.

About Vivani Medical

Vivani Medical (NASDAQ:VANI) is a clinical-stage biopharmaceutical company developing miniature, subcutaneous drug implants designed to provide continuous delivery of medicines over extended periods. Its proprietary NanoPortal technology is intended to address challenges associated with conventional dosing, including frequent injections, daily administration and inconsistent medication adherence.

The company’s development programs have focused primarily on therapies for metabolic diseases. Its NPM-115 program is designed to deliver exenatide for chronic weight management, while NPM-119 is intended to provide continuous exenatide delivery for the treatment of type 2 diabetes. Vivani has also pursued additional implantable programs involving therapies such as semaglutide for obesity and related metabolic conditions.

Vivani Medical is based in the United States and is led by President and Chief Executive Officer Adam Mendelsohn, Ph.D. As an emerging biotechnology company, Vivani’s product candidates remain subject to clinical development and regulatory review, and the company’s programs may change as research progresses.

View Vivani Medical Profile